1.Abbasvandi F, Bayat M, Akbari A, Shojaeian F, Zandi A, Rahmani J, Hashemi MO, Akbari ME. Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. Sci Rep. 2023 Oct 4;13(1):16719. doi: 10.1038/s41598-023-43186-8. PMID: 37794050; ...
The entire model comprises two parts, including a tumor cell module and multiple pharmacokinetic (PK) modules for drugs (Fig.1). Based on current knowledge and understanding of HER2+ BC proliferation and survival, we constructed a mathematical model of intracellular signaling in HER2+ BC cells...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
Background Use of targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer has led to improvements in survival. Furthermore, neoadjuvant chemotherapy (NAC) with dual HER2 agents demonstrated improved pathological complete response (pCR) rates. With these data, and ...
16. Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor‐positive, HER2‐negative, node‐positive, high‐risk early breast cancer (monarchE): results from a preplanned interim analysis of ...
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status si......
study (NCT01358877) showed that addition of pertuzumab to standard adjuvant therapy significantly improves invasive disease-free survival (DFS)5,6,7. Dual HER2 blockade evidently increases the frequency of diarrhea in HER2-positive breast cancer, but not the rate of cardiac adverse events (AEs)5,...
CONCLUSIONS Patients with early stage, HER2-positive breast cancer and normal BMI had a better 5-year DFS compared with overweight and obese women. The current results indicated that adjuvant trastuzumab improves clinical outcome regardless of BMI. Cancer 2013;119:2447-2454 . 2013 American Cancer ...
survival (DMFS) of the status HR and the status of focal peak 17q21.31 in HR-positive HER2-low breast cancers. Number (N) of patients belonging to each category is indicated. The association of all variables with prognosis was analyzed using a two-sided Cox proportional hazard regression ...
respond poorly. This study aimed to identify predictors of response in the neoadjuvant treatment and to assess the discordance rate of HER2 status between pre- and post-treatment specimens in HER2-positive breast cancer.Meth...